Single-agent doxorubicin remains the standard treatment for advanced soft tissue sarcomas. Combining doxorubicin with standard-dose ifosfamide has not been shown to improve survival and is associated with a significantly increased toxicity; it is not known whether higher dose single-agent ifosfamide is superior to doxorubicin.
INTRODUCTION
Progress in the treatment of advanced soft tissue sarcoma over the last 10 years has been slow, with the notable exception of imatinib in gastrointestinal stromal tumors (GIST). Patients with metastatic or locally advanced, inoperable disease are generally considered incurable and are treated with palliative intent. While a small proportion of these may be long-term survivors, the majority die of their disease with a median survival of 51 weeks.
1,2 Anthracyclines and ifosfamide have been established as the most active agents for metastatic soft tissue sarcoma, with reported single-agent response rates of between 10% and 36%. 3 However, treatment with doxorubicin is limited because of cumulative cardiotoxicity. A randomized comparison of two doses of epirubicin and doxorubicin showed no difference in response rate, but higher myelotoxicity for epirubicin. 4 ,5 The use of pegylated doxorubicin in liposomes showed equivalent activity in a randomized phase II trial but at the expense of greater skin toxicity. 6 It has been suggested that the response rate to ifosfamide is both dose and schedule dependent. 7, 8 A randomized phase II study comparing standard-dose ifosfamide 5 g/m 2 over 24 hours, with ifosfamide 3 g/m 2 daily for 3 days, reported a response rate of 10% for the lower-dose treatment and 25% for the higher dose. 9 In contrast, a phase II study using a higher ifosfamide dose of 12 g/m 2 reported a response rate of only 16%, at the cost of excessive toxicity. 10 However, as a result of dose reductions due to toxicity, the achieved dose intensity was only 75%. This is not unexpected as the pharmacokinetics of ifosfamide are saturable, and further dose escalation results in increased toxicity without increased levels of the active metabolite. Eight studies have compared singleagent doxorubicin with doxorubicin-based combinations.
11-18 None showed a survival advantage for combination therapy over single agent doxorubicin, and this was confirmed in a subsequent metaanalysis. 19 Many studies have compared various doxorubicin-based regimens, with no clear evidence of a benefit. [20] [21] [22] A recent phase II study comparing doxorubicin 60 mg/m 2 plus ifosfamide 6 g/m 2 or 12 g/m 2 , both given with granulocyte colony-stimulating factor support, showed significantly higher toxicity, and yet a trend toward inferior survival for the high-dose arm.
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Single-agent chemotherapy with doxorubicin remains, therefore, the standard first-line treatment for the majority of patients. However, there had never been a formal comparison of doxorubicin and ifosfamide in first-line treatment for patients with advanced and/or metastatic soft tissue sarcoma. To address this issue, the European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Saroma Group (STBSG) initiated the current study using two different schedules of ifosfamide 9 g/m 2 , based on the results of two previous phase II trials.
9,10

PATIENTS AND METHODS
Eligibility Criteria
Patients between the ages 16 and 65 years with histologically confirmed locally advanced or metastatic soft tissue sarcoma were eligible for inclusion in this study. Patients were required to have measurable disease, WHO performance status less than 2, and no prior chemotherapy. All soft tissue sarcoma subtypes were allowable, but patients with Ewing sarcoma, chondrosarcoma, osteosarcoma, and embryonal rhabdomyosarcoma were excluded. GIST had not been defined as a distinct sarcoma subgroup when the study was begun, therefore many GIST patients were not excluded. Other baseline eligibility criteria were adequate renal, hepatic, and bone marrow function (measured creatinine clearance Ͼ 70 mL/min, albumin Ͼ 25 g/L, billirubin Ͻ 30 mol/L, neutrophils Ͼ 2 ϫ 10 9 /L, platelets Ͼ 100 ϫ 10 9 /L). Exclusion criteria included a history of other malignancy, prior radiotherapy to a solitary measurable lesion, and active cardiac disease. The study was approved by the institutional review board of each participating institution. All patients gave written informed consent.
Follow-Up Studies
All patients were required to have a physical examination, performance status assessment, measured creatinine clearance, CBC and biochemistry, and tumor assessment before starting treatment. CBCs were repeated weekly.
Treatment
Doxorubicin 75 mg/m 2 was administered by intravenous bolus every 3 weeks. The ifosfamide short infusion (Ifos 3*3) was administered as follows: a bolus of mesna 0.6 g/m 2 was followed by ifosfamide 3 g/m 2 and mesna 1.5 g/m 2 in 1,000 mL of saline 0.9% over 4 hours, followed by mesna 1.2 g/m 2 either orally at 2 and 6 hours, or intravenously at 4 and 8 hours, repeated daily for 3 days. Ifosfamide 9 g/m 2 infusion (Ifos 9) was given as follows: a bolus of mesna 0.6 g/m 2 was followed by ifosfamide 3 g/m 2 in 3 L normal saline with mesna 3 g/m 2 infused intravenously over 24 hours, repeated for 3 days in total followed by either a further 1.8 g/m 2 of mesna in 1 L of dextrose saline over 12 hours, or 1.2 g/m 2 mesna orally at 0, 2, and 6 hours. Patients receiving ifosfamide also received sodium bicarbonate 150 mmol intravenously daily during the 3-day infusion. Treatment was continued every 3 weeks until documented disease progression, unacceptable toxicity, or patient refusal, to a maximum of six cycles of chemotherapy. Treatment was delayed by 1 week in the event of incomplete recovery of CBC. In the event of neutropenic fever requiring hospitalization and antibiotics, subsequent treatment was given with a 20% dose reduction. Treatment was discontinued if the serum creatinine rose above 2.5ϫ the upper limit of normal between cycles of treatment, or the measured creatinine clearance was less than 60 mL/min. Treatment was discontinued in the event of grade 3/4 neurotoxicity or if the left ventricular ejection fraction decreased to less than 45%. Patients who experienced somnolesence or other signs of encephalopathy when receiving ifosfamide were treated with methylene blue 50 mg intravenously every 4 hours until symptoms resolved, and subsequently, prophylactively starting 4 hours before the start of the next cycle of treatment until 72 hours after completion.
Evaluation of Response and Toxicity
Response to treatment was assessed after every two cycles of treatment. All responses were confirmed at least 1 month after the initial date of response. WHO criteria were used for the evaluation of response.
24 All responses were subject to EORTC STBSG peer review. In case of discrepancy between reviewers the response was down-graded. Progression-free survival (PFS) was measured from the date of registration to disease progression or last contact. Duration of survival was calculated from the date of registration to the date of death. Overall survival (OS) and PFS were estimated by the Kaplan-Meier method; differences between curves were assessed using the log-rank test. Toxicity was evaluated according to the National Cancer Institute Cancer Common Toxicity Criteria.
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Statistical Design and Independent Data Monitoring Committee
The study was designed to detect a 10% (ie, from 15% to 25%) difference in PFS at 1 year. Patients were stratified by institution, grade, and histological subtype (leiomyosarcoma v synovial sarcoma v others). To take into account the multiple comparisons and keep an overall ␣ value of .05, each comparison was performed to an ␣ of .02; ␤ was taken to be .2. A total of 780 patients was required. An independent data monitoring committee was to review the data after 163 treatment failures. In addition, an interim analysis of toxicity was planned and carried out after the first 42 patients were treated, with a plan to stop the study if the incidence of neutropenic sepsis or prolonged grade 4 hematologic toxicity (Ͼ 7 days) exceeded 25%.
RESULTS
Between February 1998 and October 2001, 326 patients were randomized by 40 institutions. Twenty-eight patients (9%) were ineligible-26 due to the delay between the baseline computed tomography scan and the start of treatment, and two had no target lesion.
This study was closed early following the advice of an independent data monitoring committee.
Patient and Tumor Characteristics
Patient characteristics are presented in Table 1 . Treatment arms were well balanced for age, sex, performance status, liver involvement, and site of primary tumor. There were more patients with a retroperitoneal primary in the doxorubicin arm.
Histologic Review
Two hundred fifty of the cases were independently reviewed by the pathology subcommittee of STBSG. Four patients were ineligible (one each of melanoma, carcinoma, mesothelioma, and osteosarcoma). Eleven cases (3.4%) were reclassified as undifferentiated and 28 cases (8.6%) as GIST. The evaluation of Trojani grade by the local and review pathologist ( Table 2) was consistent in only 150 of the 250 reviewed cases (60%); 40 cases (16%) were downgraded, and 60 cases (24%) were upgraded by the review panel.
Treatment Administered
Six patients were randomly assigned but did not receive treatment (four, refusal of allocated regimen; one, protocol violation; one, deterioration in performance status). Three hundred twenty-six patients received 1,170 cycles of treatment; 420 cycles of doxorubicin; 354 cycles of Ifos 3*3; and 393 cycles of Ifos 9. Thirty six patients (32.7%) in the doxorubicin arm, 22 (20.1%) in the Ifos 3*3 arm, and 33 (30.8%) in the Ifos 9 arm completed six cycles of chemotherapy. Treatment was discontinued because of toxicity in 1% of patients in the doxorubicin arm, 16% in the Ifos 3*3 arm and 10% in the Ifos 9 arm, (doxorubicin v Ifos 3*3, P Ͻ .001; doxorubicin v Ifos 9, P ϭ .006). Seventy-five patients (68%) in the doxorubicin arm, 87 (80%) in the Ifos 3*3 arm, and 76 (71%) in the Ifos 9 arm stopped treatment early, and in the majority of cases, this was due to progressive disease. In the 1,170 cycles there were 36 protocol violations (3%), mostly related to inappropriate dose reductions or increases. Dose intensity for the cycles administered was similar in all three arms, with 95.5% of doxorubicin patients, 91.6% of Ifos 3*3 patients, and 94.2% of Ifos 9 patients receiving more than 75% of the planned dose intensity.
Safety and Toxicity
Clinically relevant toxicities are presented in Table 3 . A higher proportion of patients in the ifosfamide arms had grade 4 neutropenia, leucopenia, and febrile neutropenia. Twenty-one episodes of grade 3 or 4 encephalopathy were recorded in 20 patients receiving ifosfamide, with none being reported for doxorubicin treated patients. Other toxicities were not different between the three groups. There were five toxic deaths (1.5%)-one in the doxorubicin arm (0.9%), three in the Ifos 3*3 arm (2.75%); and one (0.9%) in the Ifos 9 arm. There were four more deaths where the cause was unassessable-one in the Ifos 3*3 arm and three in the Ifos 9 arm.
PFS, OS, and Response Rate
With a median follow-up of 3.75 years, PFS (Fig 1) and OS (Fig 2) were not significantly different between the three arms ( Table 4 ). The overall response rate was 11.8% for doxorubicin, 5.5% for Ifos 3*3, and 8.4% for Ifos 9. The number of patients with stable disease was higher in the Ifos 9 arm, but this did not translate into an improvement in PFS (Fig 2) . Comparison of the response rates in the doxorubicin arm with the Ifos 3*3 and Ifos 9 arms showed no difference (doxorubicin v Ifos 3*3, P ϭ .12; doxorubicin v Ifos 9, P ϭ .44). When the two ifosfamide arms were compared, there seemed to be an advantage for Abbreviations: Ifos 3*3, ifosfamide 3 g/m 2 per day in 3 hours over 3 days; Ifos 9, ifosfamide 9 g/m 2 over 3 days continuous infusion. the Ifos 9 arm over the Ifos 3*3 arm (P ϭ .015), reflected in a higher number of stable disease patients, but this did not translate into an improvement in PFS or OS (Fig 3) . An independent data monitoring committee reviewed the study when 326 patients had been recruited. The conclusion of the IDMC was that the study should be closed for futility reasons, with the conclusion that no difference was observed for PFS.
DISCUSSION
The standard first-line treatment of advanced soft tissue sarcoma remains single-agent doxorubicin. Combination chemotherapy has not been shown to increase survival in this population of patients despite the higher response rates reported by several randomized trials. Single-agent high-dose ifosfamide is active in soft tissue sarcoma. This is the first study to directly compare doxorubicin and ifosfamide, the two most active single agents in soft tissue sarcoma. The group planned to enroll a total of 760 patients. However, the study was stopped early, on the advice of the data monitoring committee, for futility reasons; that is, a lack of superiority of either of the ifosfamide arms to doxorubicin-a conclusion that was reached after prolonged follow-up.
Response rates were low for all treatment arms. This is likely to be due in part to the stringent response evaluation used including independent verification. Furthermore, 30% of patients registered had leiomyosarcoma; in 49% of these, the primary tumor was gastrointestinal or retroperitoneal in origin, and central pathology review identified 8.6% of patients to have GIST.
Treatment with doxorubicin was better tolerated than either ifosfamide schedule. More patients completed six cycles of doxorubicin (33%) than either ifosfamide arm (20% and 29% for Ifos 3*3 and Ifos 9, respectively), and only 3% of patients receiving doxorubicin stopped treatment due to toxicity or withdrawal of consent, compared with 15% and 21% in the ifosfamide arms. Leucopenia and neutropenia were less marked with doxorubicin than in the two ifosfamide regimens, and this resulted in less febrile neutropenia with this treatment (8%) than in the ifosfamide arms (18% and 20% for Ifos 3*3 and Ifos 9, respectively). Neurotoxicity was a problem in the patients receiving ifosfamide, with 11% of patients experiencing grade 3 or 4 encephalopathy. Stomatitis was more common with doxorubicin, but was rarely worse than grade 2.
The Ifos 9 schedule seemed slightly better than the 3*3 schedule in terms of higher response rate and less toxicity. However, this should be interpreted with care; response rate was not a primary end point, and the higher response rate did not translate into better PFS and OS. A higher proportion of Ifos 9 patients completed six cycles of therapy (31.8% v 20.1% for Ifos 3*3 and Ifos 9, respectively) and fewer discontinued treatment due to toxicity (10.3% v 15.6% for Ifos 3*3 and Ifos 9, respectively). However, grade 3 and 4 anemia was more common with this schedule (17.6% v 11.5%) as was grade 2 and 3 nausea (43.1% v 33.4% for Ifos 3*3 and Ifos 9, respectively).
Many studies have compared single-agent doxorubicin with doxorubicin-based combinations.
11-18 None has shown a survival advantage for combination therapy over single-agent doxorubicin. Two studies showed a higher response rate for the combination. 16, 17 However a large study from the EORTC that randomly assigned patients to doxorubicin 75 mg/m ; or cyclophosphamide, vincristine, doxorubicin, and dacarbazine; reported no difference in response rate, remission duration, or OS between the three arms, though myelosuppression was more common in the doxorubicin plus ifosfamide-treated patients.
18 A subsequent meta-analysis carried out by the Cochrane Group showed no significant difference in response rate or survival for combination therapy over single-agent doxorubicin. 19 Many studies have compared various combination regimens. Antman compared the combination of doxorubicin and dacarbazine and the same regimen with the addition of ifosfamide and mesna. While response rates and time to progression were better with ifosfamide and mesna, there was a trend toward improved survival for the doublet (13.3 v 11.9 months). 20 A study comparing doxorubicin and dacarbazine with the same combination plus either cyclophosphamide or actinomycin showed no difference in outcome for the triplet regimens. 20 A randomized study comparing the combination of doxorubicin, dacarbazine, cyclophosphamide, and vincristine with an alternating schedule of doxorubicin and dacarbazine with cyclophosphamide and vincristine showed a lower response rate for the alternating combination, but no significant difference in OS. 22 The role of dose intensification in patients with advanced sarcoma is unclear. A pilot study comparing doxorubicin (60 mg/ m 2 ) and ifosfamide either at a dose 6 g/m 2 or 12 g/m 2 with granulocyte colony-stimulating factor was too small to draw any reliable conclusions. 23 However, the dose-intensified arm was associated with significantly worse toxicity and a trend toward worse survival. A phase III trial comparing standard-dose doxorubicin 50 mg/m 2 and ifosfamide 5 g/m 2 , or an intensified arm combining doxorubicin 75 mg/m 2 and ifosfamide 5 g/m 2 with granulocyte-macrophage colony-stimulating factor support showed no difference in response rate or OS, though the PFS rate was higher in the dose-intensified arm. 26 Whether the doses used in the dose-intensified arm were still too low is being addressed in the current EORTC phase III study randomly assigning patients to either doxorubicin 75 mg/m 2 or doxorubicin 75 mg/m 2 ϩ ifosfamide 10 g/m , and hematopoietic stem-cell support as consolidation therapy in the phase II setting, and this strategy is being evaluated in an ongoing study.
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A number of studies have examined prognostic factors in soft tissue sarcomas. A review of 2,185 patients from the EORTC showed that absence of liver metastases, young age, and high-grade tumor were associated with a higher response to treatment, whereas performance status, low histologic grade, and a long disease-free interval were associated with an improved OS. 2 There is evidence that some histologic subtypes are more sensitive to chemotherapy than others. Response rates for leiomyosarcoma are generally accepted as being lower than for synovial sarcoma, with the series from the EORTC reporting PFS rates at 3 months of 44% and 77%, respectively.
28-31 Because of the small numbers of patients in each subgroup in this study, it is not possible to comment reliably on whether individual histologic subtypes responded differently to chemotherapy, or were more likely to be long-term survivors (Ͼ 3 years; Appendix Table A1 , online only). A metaanalysis of all first-line ifosfamide-based regimens is ongoing.
There was significant discrepancy between the local pathology report and the central review for both histologic subtype and Trojani grade. This shows the importance of independent pathology review in any prospective study of soft tissue sarcoma. These discrepancies may invalidate the initial stratification based on histologic type and grade. New developments will hopefully come with improvement in our understanding of the molecular genetics of sarcoma and identification of targets for new drugs. Standard-dose doxorubicin was as effective as, and better tolerated than the two ifosfamide regimens examined, and remains the treatment of choice for the majority of patients with advanced soft tissue sarcoma.
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